<DOC>
	<DOCNO>NCT01041508</DOCNO>
	<brief_summary>Stem cell transplant important therapeutic option pediatric patient relapse refractory leukemia . Although , full myeloablative transplant widely use patient acute leukemia , myeloablative chemo-radiotherapy may feasible specific setting . These setting include 1 ) patient pre-existing health issue organ toxicity ; 2 ) patient relapse post-ablative transplant need second stem cell transplant ; 3 ) leukemia patient advance disease heavily pre-treated . Clofarabine , new purine nucleoside anti-metabolite , advantage significant antileukemic activity addition possible immuno-suppressive property . In study plan determine maximum feasible dose ( MFD ) Clofarabine combination total body irradiation achieve durable donor engraftment without cause excessive toxicity .</brief_summary>
	<brief_title>Clofarabine Low Dose Total Body Irradiation Preparative Regimen Stem Cell Transplant Leukemia .</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Patients must great equal 1 less equal 21 year age study entry . Patients must diagnosis ALL AML . ALL patient must clinical remission define BM morphology &lt; 5 % blast CNS 1 status . AML patient must M1 ( &lt; 5 % blast ) M2 ( &lt; 20 % blast ) marrow status CNS 1 status . Patient must ANC great equal 750/ul . Patient must one appropriate donor type describe : 1 . HLA identical sibling donor . 2 . Complete match unrelated donor , ( match A , B , C , DR B1 DQ , B1 allelic level base high resolution type Class I II antigen , 10/10 match ) . 3 . 1 allelic mismatch unrelated donor ( antigen mismatch allow ) . The stem cell source donor must one following : 1 . Bone Marrow Peripheral blood stem cell ( PBSC ) match related donor . 2 . PBSC unrelated donor . ( Bone marrow acceptable unrelated donor ) Karnofsky &gt; 50 % patient &gt; 10 year age Lansky &gt; 50 % patient le equal 10 year age . Female patient childbearing potential must negative serum pregnancy test confirm within 2 week prior enrollment . Female patient infant must agree breastfeed infant study . Male female patient childbearing potential must agree use effective method contraception approve investigator study . Patients must calculate creatinine clearance ≥ 70mL/min/m2 calculate Schwartz formula estimate glomerular filtration rate ( GFR ) GFR ( ml/min/1.73 m2 ) = k * Height ( cm ) /serum creatinine ( mg/dl ) . K proportionality constant varies age function urinary creatinine excretion per unit body size ; 0.45 12 month age ; 0.55 child adolescent girl ; 0.70 adolescent boy . Total serum bilirubin &lt; 2 mg/dL . Aspartate transaminase ( AST ) alanine transaminase ( ALT ) less equal 5 × ULN . Patient must shorten fraction ( SF ) &gt; 25 % . If SF &lt; 25 % , patient must ejection fraction ( EF ) MUGA &gt; 30 % . Patient must pulmonary function define : 1 . DLCO &gt; 30 % 2 . FVC/TLC &gt; 30 % 3 . FEV1 &gt; 30 % predict 4 . Patient continuous oxygen If patient old enough unable comply pulmonary function test , must pulse ox &gt; 92 % room air continuous oxygen . Patient must sign informed consent Patients exclude evidence active , progressive invasive infection . All patient exist infection time study entry discuss study chair . Patients may stable invasive infection still eligible . Patients infection responsive medical surgical treatment show radiographic microbial assessment may still eligible . Patients exclude active , uncontrolled systemic fungal , bacterial , viral infection . All patient exist infection time study entry discuss study chair . •An active uncontrolled infection define exhibit ongoing sign symptom related infection ( fever , positive blood culture , chill , tachycardia , etc ) despite appropriate antibiotic treatment . Patient diagnosis CML MDS . Patient CNS 2 CNS 3 status . Patient HIV positive . Current plan treatment chemotherapy , radiation therapy , immunotherapy specify protocol . Use investigational agent within 30 day anticancer therapy within 2 week study entry . Have severe concurrent disease , history serious organ dysfunction disease involve heart , kidney ( include dialysis patient ) , liver , organ system may place patient undue risk undergo treatment . Patients systemic fungal , bacterial , viral , infection control ( define exhibit ongoing signs/symptoms related infection without improvement , despite appropriate antibiotic treatment ) . Any significant concurrent disease , illness , psychiatric disorder social issue would compromise patient safety compliance , study participation , follow , interpretation study result .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>ALL</keyword>
	<keyword>AML</keyword>
	<keyword>Recurrence</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Stem Cell Transplant</keyword>
	<keyword>Non-myeloablastive</keyword>
</DOC>